These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 580992)

  • 1. The effect of plasma fibrinogen levels on measures of fibrinolytic activity.
    Chakrabarti R; North WR; Meade TW
    Thromb Haemost; 1978 Apr; 39(2):450-4. PubMed ID: 580992
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new euglobulin clot lysis assay for global fibrinolysis.
    Smith AA; Jacobson LJ; Miller BI; Hathaway WE; Manco-Johnson MJ
    Thromb Res; 2003; 112(5-6):329-37. PubMed ID: 15041279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of breast cancer and mastectomy on fibrinolytic activity in African women.
    Famodu ES; Fakoya AA; Barhua TA; Osime CO; Egwaikhide E; Egbagbe EE; Olu-Edo AN; Osime EO
    Afr J Reprod Health; 2006 Dec; 10(3):114-9. PubMed ID: 17518138
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ascites fluid as a possible origin for hyperfibrinolysis in advanced liver disease.
    Agarwal S; Joyner KA; Swaim MW
    Am J Gastroenterol; 2000 Nov; 95(11):3218-24. PubMed ID: 11095345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sex differences in the determinants of fibrinolytic activity.
    MacCallum PK; Cooper JA; Howarth DJ; Meade TW; Miller GJ
    Thromb Haemost; 1998 Mar; 79(3):587-90. PubMed ID: 9531046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measurement of fibrinopeptide A in human blood.
    Nossel HL; Yudelman I; Canfield RE; Butler VP; Spanondis K; Wilner GD; Qureshi GD
    J Clin Invest; 1974 Jul; 54(1):43-53. PubMed ID: 4600045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasma homocysteine affects fibrin clot permeability and resistance to lysis in human subjects.
    Undas A; Brozek J; Jankowski M; Siudak Z; Szczeklik A; Jakubowski H
    Arterioscler Thromb Vasc Biol; 2006 Jun; 26(6):1397-404. PubMed ID: 16574890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters.
    Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N
    Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Behaviour of fibrinolysis in the nephrotic syndrome.
    Cucuianu M; Manasia M; Spînu C; Mărcuşu C; Roman S; Comănescu A
    Med Interne; 1988; 26(2):109-14. PubMed ID: 3133746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
    Matsuo O; Rijken DC; Collen D
    Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma fibrinolytic activity following oral anabolic steroid therapy.
    Walker ID; Davidson JF; Young P; Conkie JA
    Thromb Diath Haemorrh; 1975 Sep; 34(1):236-45. PubMed ID: 1103357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.
    Erem C
    Clin Endocrinol (Oxf); 2006 Mar; 64(3):323-9. PubMed ID: 16487444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo measurements of fibrin formation and fibrinolysis in operable breast cancer.
    McCulloch P; Douglas J; Lowe GD; Murray G; George WD
    Thromb Haemost; 1989 Apr; 61(2):318-21. PubMed ID: 2749603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serial changes in plasma fibrinogen concentration and fibrinolytic activity in African women on oral contraceptive pills.
    Famodu AA
    Afr J Reprod Health; 1997 Sep; 1(2):90-5. PubMed ID: 10214418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrinolytic activity in children with Plasmodium falciparum malaria.
    Omoigberale AI; Abiodun PO; Famodu AA
    East Afr Med J; 2005 Feb; 82(2):103-5. PubMed ID: 16122100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue-type plasminogen activator (t-PA) and dilute blood clot lysis time in nephrotic patients.
    Cucuianu MP; Rus HG; Roman S; Mărcuşu C; Spînu C; Manasia M; Niculescu F
    Thromb Haemost; 1989 Apr; 61(2):270-4. PubMed ID: 2501897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effect of a single administration of plasminogen tissue activator on the state of the fibrinolytic system of rat blood].
    Andreenko GV; Shimonaeva EE; Liutova LV; Serebriakova TN
    Vopr Med Khim; 1981; 27(1):77-80. PubMed ID: 7193381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fibrinolytic activity in Nigerian diabetics with renal insufficiency.
    Unuigbe EI; Famodu AA; Umunna CE
    Clin Hemorheol Microcirc; 2005; 32(1):13-7. PubMed ID: 15665422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibrinopeptide A (FPA) level and fibrinogen kinetics in patients with malignant disease.
    Yoda Y; Abe T
    Thromb Haemost; 1981 Dec; 46(4):706-9. PubMed ID: 7330820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alpha 2-antiplasmin, plasminogen activator inhibitor (PAI) and dilute blood clot lysis time in selected disease states.
    Cucuianu M; Knauer O; Roman S
    Thromb Haemost; 1991 Nov; 66(5):586-91. PubMed ID: 1725069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.